PDS Biotech Announces Conference Call and Webcast for Third Quarter 2025 Financial Results

Core Viewpoint - PDS Biotechnology Corporation is set to host a conference call on November 13, 2025, to report its financial results for Q3 2025 and provide updates on its clinical programs [1][2]. Company Overview - PDS Biotechnology is a late-stage immunotherapy company focused on enhancing the immune system's ability to target and eliminate cancers [3]. - The company has initiated a pivotal clinical trial for its lead program targeting advanced HPV16-positive head and neck squamous cell cancers [3]. - PDS0101 (Versamune HPV), the company's lead investigational targeted immunotherapy, is being developed in combination with a standard immune checkpoint inhibitor and in a triple combination with PDS01ADC and a standard immune checkpoint inhibitor [3]. - PDS01ADC, an IL-12 fused antibody drug conjugate, is currently being evaluated in multiple phase 2 trials across various cancer indications [3]. Conference Call Details - The conference call is scheduled for November 13, 2025, at 8:00 a.m. Eastern Time [2]. - Dial-in numbers are provided for both domestic and international participants [2]. - The event will be archived on the company's website for six months following the live webcast [2]. Contact Information - Investor contact is Mike Moyer from LifeSci Advisors, reachable at +1 (617) 308-4306 [7]. - Media contact is David Schull from Russo Partners, reachable at +1 (858) 717-2310 [7].